Electromed, Inc. Form 10-Q Summary
Business Context and Reporting Period
Electromed develops, manufactures, and markets airway-clearance products using High Frequency Chest Wall Oscillation therapy, primarily the SmartVest system. The company serves home-care, institutional, government, and international markets. This unaudited report covers the three months ended September 30, 2014, the first quarter of fiscal 2015, and was filed November 12, 2014.
Key Financial Metrics
| Metric | Q1 FY2015 | Q1 FY2014 |
|---|---|---|
| Net revenue | $4.771 million | $3.418 million |
| Gross profit | $3.295 million | $2.356 million |
| Gross margin | 69.1% | 68.9% |
| Operating income (loss) | $398,000 | $(577,000) |
| Net income (loss) | $378,000 | $(335,000) |
| Basic and diluted EPS | $0.05 | $(0.04) |
| Net cash from operating activities | $945,000 | $742,000 |
| Capital expenditures | $157,000 | $149,000 |
Revenue increased 39.6%, led by home-care revenue of $3.841 million, international revenue of $399,000, and government/institutional revenue of $531,000. Cash and cash equivalents were $2.280 million at September 30, 2014, compared with $1.503 million at June 30, 2014. Working capital was approximately $9.2 million.
Total liabilities were $3.402 million and total equity was $13.113 million at September 30, 2014. Debt consisted primarily of approximately $1.268 million outstanding under a term loan, including $47,000 classified as current debt. The $2.5 million revolving credit line had no outstanding balance. The company reported no off-balance-sheet arrangements.
Material Changes Versus the Prior Comparable Period
- Revenue increased by $1.353 million, or 39.6%.
- Home-care revenue rose 35.1%, attributed to improved reimbursement operations, new third-party payer contracts, faster approval cycles, higher average selling prices, and improved referral-to-approval rates.
- International revenue rose 167.8%, partly due to European Union distributors accelerating purchases before the company’s SmartVest system achieved RoHS 2 compliance.
- Gross margin improved modestly despite higher manufacturing costs for the SmartVest SQL.
- SG&A increased 3.6% to $2.821 million, primarily from higher commissions and additional reimbursement personnel.
- Research and development expense declined 64.1% to $75,000 following completion of SmartVest SQL launch activities.
- The company returned to operating and net profitability from losses in the prior-year quarter.
- Operating cash flow increased approximately $203,000, while cash increased $777,000 during the quarter.
- The prior-year period included a $257,000 income tax benefit; no income tax expense was recorded in the current quarter because net operating loss carryforwards offset taxable income.
Guidance, Outlook, Risks, and Unusual Items
- Management expects long-term gross margins to return to historical levels above 70% as sales growth improves manufacturing-cost leverage.
- Long-term research and development spending is expected to be approximately 2% to 4% of net revenue, although quarterly spending may fluctuate.
- The company expects to offer SmartVest SQL to institutional and international customers, but had not determined a specific timeframe.
- Management expected to resume shipments to European Union distributors during the second half of fiscal 2015 after addressing RoHS 2 compliance.
- The revolving credit line expired December 18, 2014 if not renewed. Management believed renewal or alternative financing was likely but stated that financing on favorable terms was not guaranteed.
- The credit facility includes a minimum tangible net worth covenant of $10.125 million and restrictions on additional indebtedness and dividends. The company was in compliance at September 30, 2014, after a prior covenant violation in March 2014 was waived and the covenant threshold was amended.
- Failure to comply with covenants or renew the facility could result in accelerated debt maturity, loss of borrowing availability, foreclosure on secured assets, or insufficient liquidity to continue operations as planned.
- Key disclosed risks include reimbursement changes, healthcare-law changes, regulatory compliance, international-market expansion, competition, sales-force execution, intellectual-property claims, financing availability, and general economic conditions.
- The company maintains a $720,000 warranty reserve, including lifetime warranties for prescribed U.S. patients and three-year warranties for institutional and non-U.S. sales.
- Management reported no material undisclosed litigation and concluded that disclosure controls and procedures were effective.
Important Facts for Investors to Verify
- Whether the revolving credit facility was renewed or replaced before its December 18, 2014 expiration.
- Whether the company sustained revenue growth and gross margins above 70% after the SmartVest SQL launch.
- The timing and financial impact of RoHS 2 compliance and the resumption of European Union shipments.
- Whether net operating loss carryforwards continue to eliminate cash tax expense and how the deferred-tax valuation allowance changes.
- Compliance with the $10.125 million tangible net worth covenant and the company’s remaining term-loan obligations.
- Trends in reimbursement approvals, payer contracts, accounts receivable, warranty claims, and international distributor purchases.